Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications
New findings from an international study suggest that a combination of amylin and glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatments may enhance blood glucose control and support weight loss in adults with type 2 diabetes. Researchers presented data from the REIMAGINE clinical trials at the American Diabetes Association's 2026 Scientific Sessions held in New Orleans.
Amylin, produced in the pancreas alongside insulin, is being explored as a therapeutic target for diabetes and obesity. The REIMAGINE clinical trial program evaluated CagriSema, a fixed-dose combination of cagrilintide, which mimics amylin, and semaglutide, a GLP-1 RA. The program aims to determine the effectiveness and safety of CagriSema for adults with type 2 diabetes across various studies.
The REIMAGINE 1 trial included 189 patients who had not responded to diet or exercise alone. Results indicated that the CagriSema treatment improved blood glucose levels and encouraged weight loss. The findings suggest that this combined approach may lead to diabetes remission with a once-weekly injection. Lead author Vanita R. Aroda, MD, emphasized the potential of early combination treatment to address multiple health factors rather than simply focusing on glucose control.
The REIMAGINE 2 trial, which involved 2,728 participants, revealed that CagriSema was more effective at lowering blood glucose levels compared to semaglutide alone and resulted in greater weight loss than existing therapies. Lead author Akshay B. Jain, MD, FRCPC, stated that the combination treatment enhances outcomes for patients who need improved glycemic control.
Additionally, the REIMAGINE 3 trial demonstrated significant benefits for 274 adults with long-standing type 2 diabetes inadequately controlled by basal insulin. The study found that CagriSema led to meaningful blood glucose improvements and weight loss without increasing hypoglycemia risks. Lead author Julio Rosenstock, MD, noted the importance of these results for patients facing challenges in diabetes management.
Further analyses from these studies are ongoing, with updates expected as part of the broader REIMAGINE program. The American Diabetes Association's Scientific Sessions from June 5-8 brought together healthcare professionals worldwide to discuss advancements in diabetes research and treatment.